News from Europe's pharmaceutical manufacturing industry coupled with upcoming events, and exclusive articles and interviews from industry experts. WEEKLY
PHOTOGRAPHY BY DAN WARD; MIKE HARRINGTON/GETTY IMAGES
The spate of large mergers that dominated the news a few years ago seems to be slowing, but bio/pharmaceutical companies still
face pressure to run leaner businesses and to see a better return on investment from their R&D divisions. The global economy
continues to limp along, and pharma faces pricing pressure from cost-conscious payers and from developing countries determined
to hold the line on drug prices. The industry continues to adapt to this challenging business environment, and these challenges
cannot help but affect pharma employees. Pharmaceutical Technology asked readers about their employment situations: how secure they felt in their positions, how satisfied they are with their
jobs, and how they see the future of their companies and the global industry. The following pages highlight key results from
the survey.
The level of employment insecurity is dropping among biopharma employees. Year over year, fewer respondents say they feel
less secure in their positions than they did the year before. In 2010, 53% said they felt less secure. This dropped to 41%
in 2011, and this year, only 34% were feeling less secure. While this seems encouraging, readers did not say they felt more
secure. Instead, an increased percentage (47% this year) said they felt about the same as last year. It seems, then, that
pharma employees are becoming accustomed to the new, more fluid business environment. Is insecurity becoming the new normal?
Perhaps, but respondents felt confident they would be able to find a new job if they had to, and they continue to derive satisfaction
from the intellectual stimulation and challenging projects associated with their jobs.
The difficult economic climate is being felt by those in the industry. A third of respondents, 33%, indicated that business
had declined over the past year. Yet, respondents were upbeat about the future, both for their own companies and for the industry
as a whole. Only 34% expect business at their own companies to decline next year, with the rest expecting either no change
(18%), or an increase (48%). When asked about the industry as a whole, 49% said they expected business to improve. Next year
will bring its own set of challenges for the industry, but let's hope that this optimism is well founded.
Amy Ritter is Scientific Editor, BioPharm International and Pharmaceutical Technology.
Amy Ritter joined the editorial staff of BioPharm International and Pharmaceutical Technology in 2011. She received her BA in Biology from Boston University, and holds a PhD in Neurobiology from SUNY at Stony Brook. Before joining Advanstars Pharm Sciences group, she worked in the preclinical pharmacology group at Merck Research Labs, and is the author of numerous peer-reviewed scientific publications.
Articles by Amy Ritter
Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
